Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ruxolitinib Phosphate

FDA-approved product (tablet, oral), marketed as Leqselvi, Jakafi, Jakafi Xr and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ruxolitinib Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alopecia areata
  • Cancer
  • Eczematoid dermatitis
  • Graft versus host disease
  • Myelofibrosis
  • Myeloproliferative disorder
  • Neoplasm
  • Polycythemia vera
  • Primary myelofibrosis
  • Vitiligo

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor; Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ruxolitinib Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ruxolitinib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

    NCT04908280 · start 2022-05-04

    Registered record
    Registry ID
    NCT04908280
    Conditions
    Discoid Lupus Erythematosus
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-05-04
    Completion
    2024-03-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiscoid Lupus Erythematosus
    InterventionRuxolitinib
    PhasePhase 2
    Registry statusCompleted

  • Ruxolitinib in Thrombocythemia and Polycythemia Vera

    NCT04644211 · start 2022-03-21

    Registered record
    Registry ID
    NCT04644211
    Conditions
    Essential Thrombocythemia; Polycythemia Vera
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-03-21
    Completion
    2034-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia; Polycythemia Vera
    InterventionRuxolitinib
    PhasePhase 2
    Registry statusRecruiting

  • Ruxolitinib for Cancer Cachexia

    NCT04906746 · start 2022-02-23

    Registered record
    Registry ID
    NCT04906746
    Conditions
    Stage IV Non-small Cell Lung Cancer; Cachexia
    Interventions
    Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2022-02-23
    Completion
    2026-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IV Non-small Cell Lung Cancer; Cachexia
    InterventionIdentify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

    NCT05037760 · start 2021-12-16

    Registered record
    Registry ID
    NCT05037760
    Conditions
    Myelofibrosis
    Interventions
    Elritercept; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-12-16
    Completion
    2030-02-28
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis
    InterventionElritercept; Ruxolitinib
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Ruxolitinib and Duvelisib in People With Lymphoma

    NCT05010005 · start 2021-08-12

    Registered record
    Registry ID
    NCT05010005
    Conditions
    T-cell Lymphomas; NK-Cell Lymphomas; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocyte Leukemia
    Interventions
    Ruxolitinib; Duvelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-08-12
    Completion
    2027-08
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT-cell Lymphomas; NK-Cell Lymphomas; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocyte Leukemia
    InterventionRuxolitinib; Duvelisib
    PhasePhase 1
    Registry statusRecruiting

  • To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

    NCT04551066 · start 2021-05-24

    Registered record
    Registry ID
    NCT04551066
    Conditions
    Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
    Interventions
    parsaclisib; ruxolitinib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-05-24
    Completion
    2024-11-25
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
    Interventionparsaclisib; ruxolitinib; placebo
    PhasePhase 3
    Registry statusTerminated

  • ECP Combination Study

    NCT05052385 · start 2021-04-13

    Registered record
    Registry ID
    NCT05052385
    Conditions
    Steroid Refractory GVHD
    Interventions
    Ruxolitinib; Extracorporeal photopheresis; Ibrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-04-13
    Completion
    2022-06-15
    Enrolment
    319

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSteroid Refractory GVHD
    InterventionRuxolitinib; Extracorporeal photopheresis; Ibrutinib
    PhaseNot recorded
    Registry statusCompleted

  • Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera

    NCT06078319 · start 2021-01-18

    Registered record
    Registry ID
    NCT06078319
    Conditions
    Adherence, Patient; Adherence, Treatment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-18
    Completion
    2023-06-30
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdherence, Patient; Adherence, Treatment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

    NCT05021276 · start 2020-12-15

    Registered record
    Registry ID
    NCT05021276
    Conditions
    Safety and Efficacy
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-15
    Completion
    2022-12-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Efficacy
    InterventionRuxolitinib
    PhasePhase 4
    Registry statusUnknown

  • A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease

    NCT04424056 · start 2020-09-01

    Registered record
    Registry ID
    NCT04424056
    Conditions
    Covid19
    Interventions
    Anakinra +/- Ruxolitinib (stages 2b/3); Anakinra and Ruxolitinib (Advanced stage 3); Tocilizumab +/- ruxolitinib (stages 2b/3); Tocilizumab and Ruxolitinib (Advanced stage 3); Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2022-11-01
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionAnakinra +/- Ruxolitinib (stages 2b/3); Anakinra and Ruxolitinib (Advanced stage 3); Tocilizumab +/- ruxolitinib (stages 2b/3); Tocilizumab and Ruxolitinib (Advanced stage 3) +1 more
    PhasePhase 3
    Registry statusUnknown

  • Ruxolitinib and Decitabine for High Risk Hematological Malignancies

    NCT04582604 · start 2020-09-01

    Registered record
    Registry ID
    NCT04582604
    Conditions
    Peripheral Blood Stem Cell Transplantation
    Interventions
    modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2025-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Blood Stem Cell Transplantation
    Interventionmodified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

    NCT04477993 · start 2020-08-14

    Registered record
    Registry ID
    NCT04477993
    Conditions
    Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2
    Interventions
    Janus Kinase Inhibitor (ruxolitinib); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2020-08-14
    Completion
    2021-03-29
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2
    InterventionJanus Kinase Inhibitor (ruxolitinib); Placebo
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

    NCT04331665 · start 2020-05-21

    Registered record
    Registry ID
    NCT04331665
    Conditions
    COVID-19; Pneumonia
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-05-21
    Completion
    2021-03-24
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19; Pneumonia
    InterventionRuxolitinib
    PhaseNot applicable
    Registry statusTerminated

  • Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

    NCT03774082 · start 2020-05-20

    Registered record
    Registry ID
    NCT03774082
    Conditions
    Graft vs Host Disease
    Interventions
    INC424
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-20
    Completion
    2024-08-26
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft vs Host Disease
    InterventionINC424
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting